Frizzled-8 decoy receptor (FZD8-Fc)

The Frizzled-8 decoy receptor interface represents a therapeutic target site where soluble Frizzled-8 (FZD8) protein fragments compete with endogenous receptors for Wnt ligand binding. This interface is primarily formed by the extracellular cysteine-rich domain (CRD) of FZD8, which possesses a high-affinity binding pocket for the palmitoleoyl group and protein core of various Wnt ligands, such as Wnt1 and Wnt3a (Janda et al., 2012, Science). By occupying this interface, decoy molecules like Ipafricept (OMP-54F28) effectively sequester Wnt proteins, preventing the formation of the Wnt-Frizzled-LRP5/6 signaling complex on the cell membrane (Le et al., 2015, Journal of Clinical Oncology). This blockade inhibits the canonical Wnt/beta-catenin pathway, a key driver of oncogenesis and cancer stem cell self-renewal in several malignancies, including pancreatic and ovarian cancers (Jimeno et al., 2017, Clinical Cancer Research). Despite its potent anti-tumor potential, targeting this interface poses challenges due to the essential role of Wnt signaling in physiological processes such as bone homeostasis and intestinal crypt maintenance (Moore et al., 2019, Investigational New Drugs). Consequently, clinical development of drugs targeting this interface requires careful monitoring of bone mineral density and the use of bone-protective agents like bisphosphonates (Smith et al., 2013, American Society of Clinical Oncology).

Other names

IpafriceptOMP-54F28Frizzled-8 cysteine-rich domain-Fc fusion proteinFZD8-CRD-hFcSoluble Frizzled-8 receptor

Competitive sequestration of Wnt ligands to prevent their binding to endogenous cell-surface Frizzled receptors and LRP5/6 co-receptors, thereby inhibiting the canonical Wnt/beta-catenin signaling pathway.